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ARTICLE
Purine metabolism regulates DNA repair and
therapy resistance in glioblastoma
Weihua Zhou1,14, Yangyang Yao1,2,14, Andrew J. Scott1,3,14, Kari Wilder-Romans1, Joseph J. Dresser1,
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Intratumoral genomic heterogeneity in glioblastoma (GBM) is a barrier to overcoming
therapy resistance. Treatments that are effective independent of genotype are urgently
needed. By correlating intracellular metabolite levels with radiation resistance across dozens
of genomically-distinct models of GBM, we find that purine metabolites, especially guany-
lates, strongly correlate with radiation resistance. Inhibiting GTP synthesis radiosensitizes
GBM cells and patient-derived neurospheres by impairing DNA repair. Likewise, adminis-
tration of exogenous purine nucleosides protects sensitive GBM models from radiation by
promoting DNA repair. Neither modulating pyrimidine metabolism nor purine salvage has
similar effects. An FDA-approved inhibitor of GTP synthesis potentiates the effects of
radiation in flank and orthotopic patient-derived xenograft models of GBM. High expression
of the rate-limiting enzyme of de novo GTP synthesis is associated with shorter survival in
GBM patients. These findings indicate that inhibiting purine synthesis may be a promising
strategy to overcome therapy resistance in this genomically heterogeneous disease.
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G lioblastoma (GBM) is the most common aggressive adultprimary brain tumor and is associated with profoundgenomic heterogeneity, which has limited therapy devel-
opment. Work from The Cancer Genome Atlas (TCGA) and
others have defined a diversity of molecular driver alterations in
GBM1,2. Unfortunately, targeted therapies against these
abnormalities have lacked efficacy in patients3–6. These dis-
appointing results may be due to the profound intratumoral
genomic heterogeneity of GBM. Indeed, single-cell and regional
sequencing have shown that driver molecular events vary region-
to-region and cell-to-cell within a single GBM7–9. This hetero-
geneity may explain why the only therapies that have improved
survival in GBMs do not require a precise molecular alteration for
activity: radiation (RT), temozolomide, surgery, and tumor
treating fields10.
RT is a critical treatment modality for GBM patients11 and RT-
resistance is a primary cause of recurrence and death. Fewer than
10% of patients with GBM live for 5 years and ~80% recur within
the high dose RT field12,13. Thus, efforts to overcome RT-
resistance are likely to improve outcomes in patients with GBM.
Efforts to develop strategies to overcome RT-resistance have
previously used large-scale genomic profiling data to define
candidate oncogenic molecular alterations to target in combina-
tion with RT14–16. Due to the genomic heterogeneity of GBM and
the disappointing performance of targeted therapies in GBM3–6,
we instead sought to define therapeutic strategies that could
overcome RT-resistance independently of genotype.
Altered metabolism is a hallmark of cancers including GBM, is
regulated by cell-intrinsic and -extrinsic factors, and could
potentially regulate therapy resistance independently of geno-
type17–21. Importantly, disparate oncogenic alterations can acti-
vate common metabolic pathways, such as glycolysis22. Thus,
GBMs with profound intratumoral genomic heterogeneity may
have relatively common metabolic phenotypes that in turn
mediate resistance to RT.
Here, we find that purine metabolites cause GBM RT-
resistance by promoting the repair of RT-induced DNA double-
stranded breaks (DSBs). Depleting purines with FDA-approved
drugs radiosensitizes multiple GBM models in vitro and in vivo,
including in an orthotopic patient-derived xenograft (PDX). High
expression of inosine monophosphate dehydrogenase 1
(IMPDH1), a rate limiting enzyme in de novo GTP synthesis, is
associated with inferior survival in GBM. These findings indicate
that inhibiting purine synthesis may be a promising strategy to
overcome therapy resistance in this genomically heterogeneous
disease.
Results
Purines correlate with GBM RT-resistance. To determine the
characteristics of RT-resistance in GBM, we performed clono-
genic survival assays on 23 immortalized GBM cell lines and
found a wide distribution of intrinsic RT sensitivities (reported as
Dmid, which is the mean inactivating dose of RT and defined as
the area under the clonogenic cell survival curve23) (Fig. 1a).
These lines were chosen because they had been genomically
profiled by the Cancer Cell Line Encyclopedia (CCLE), were
publicly available from cell line repositories (ATCC, DSMZ, and
JCRB) and were amenable to both reproducible metabolomic
analysis and the clonogenic survival assay in a uniform media
(DMEM). None had mutations in isocitrate dehydrogenase 1 or 2
(IDH1/2) and thus were models of primary GBM. Intrinsic RT-
resistance did not correlate with proliferation rate (Supplemen-
tary Fig. 1A) or cell cycle distribution (Supplementary Fig. 1B).
RT causes DNA double-stranded breaks (DSBs) in DNA and
the rapid phosphorylation of histone H2A variant H2AX, which
can be readily detected by immunoblot, flow cytometry or
immunofluorescence24. Both RT-resistant (U87 MG and A172)
and -sensitive cell lines (KS-1 and U118 MG) had high levels of γ-
H2AX staining at 30 min and 2 h after RT (Fig. 1b) as measured
by flow cytometry. However, γ-H2AX staining returned to
baseline by 24 h after RT in the RT-resistant lines, while it
remained persistently elevated in the RT-sensitive lines. Thus,
RT-resistance in this GBM cell line panel is associated with an
ability to effectively repair RT-induced DSBs.
Our group and others have postulated that abnormal
metabolism in GBM may cause RT-resistance25,26. Using
transcriptional data obtained from the CCLE, we asked whether
expression of metabolic enzymes could predict for GBM RT-
resistance. Consistent with our prior work25, increased expression
of IDH1 was associated with GBM RT-resistance (Supplementary
Fig. 1C), presumably because this enzyme is an important source
of NADPH in GBM. Glutamine synthetase (GLUL) expression
was also associated with RT-resistance (Supplementary Fig. 1D),
consistent with prior reports27. IDH3a, a critical mediator of
oxidative ATP production through the TCA cycle, was instead
associated with RT-sensitivity (Supplementary Fig. 1E). Gene set
enrichment analysis revealed that three out of the top 10 most
associated gene sets with RT-sensitivity were related to oxidative
ATP production (Supplementary Fig. 1F). No such metabolic
gene sets were found among the top 10 associated gene sets with
RT-resistance (Supplementary Fig. 1G). This relative lack of
actionable metabolic targets suggested a need to measure
metabolism itself rather than the levels of metabolism-related
transcripts.
We therefore performed targeted metabolomic analysis on each
of the 23 GBM cell lines during unperturbed exponential growth
(These data accompany this manuscript as Supplementary
Data 1). Metabolites were grouped into corresponding pathways
and correlations between pathway-level changes and RT-
resistance were determined to identify metabolic phenotypes
associated with RT-resistance. Downregulation of metabolites
involved in de novo purine synthesis (inosinates and guanylates)
were positively correlated with RT-sensitivity (p < 0.03, Fig. 1c
and Supplementary Fig. 1H; Supplementary Data 1). Down-
regulation of the cytidine pathway was the third most-correlated
metabolic pathway with RT-sensitivity, but was not statistically
significant (p= 0.08). Thus, GBMs with lower nucleotide pools,
especially purines, were more likely to be RT-sensitive.
We then asked how purine metabolism changed after cells were
exposed to RT. Two hours after RT, a time point when DNA
damage had occurred (Fig. 1b) but cells had not yet arrested or
died (Supplementary Fig. 1B), both purine and pyrimidine
metabolites increased in RT-resistant cell lines (Fig. 1d; Supple-
mentary Data 1). RT-sensitive cell lines, however, increased
neither purines nor pyrimidines following RT (Fig. 1d; Supple-
mentary Data 1). In the post-RT setting, depleted guanylates was
again the metabolic feature most correlated with RT-sensitivity
(p= 0.0001, Fig. 1e; Supplementary Data 1). Decreased levels of
metabolites related to glutathione, the primary cellular antiox-
idant, were significantly associated with RT-sensitivity (p= 0.02),
which is consistent with the well-known oxidative mechanism by
which RT kills cells28. Depletion of adenylates, the other main
purine species, was also significantly associated with RT-
sensitivity (p= 0.0495, Fig. 1e; Supplementary Data 1). Together,
these results suggested that high levels of nucleobase-containing
metabolites, especially purines, were related to GBM RT-
resistance.
Nucleoside supplementation protects GBMs from RT. We next
sought to determine whether the relationship between high
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nucleobase-containing metabolites and RT-resistance in GBM
was causal. Nucleotide-poor RT-sensitive GBM cell lines were
supplemented with cell-permeable nucleosides (cytidine, guano-
sine, uridine, guanosine, and thymidine at concentrations 80–240
μM) and RT-sensitivity was determined by clonogenic assay
(Fig. 2a). RT-sensitive GBM cell lines (U118 MG, DBTRG-05MG,
and GB-1; Fig. 1a) were protected from RT by exogenous
nucleosides with Enhancement Ratios (ERs) ranging between 0.6
and 0.8 (Fig. 2b–d). ER of RT is defined as Dmid control divided
by Dmid treatment. ERs below 1 indicate radioprotection and
above 1 indicate radiosensitization. The RT-protection conferred
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Indeed, in all three sensitive cell lines, RT alone caused a peak of
γ-H2AX foci within 30 min that did not return to baseline by 24
h, whereas treatment with exogenous nucleosides decreased γ-
H2AX foci at 0.5, 2, 6, and 24 h following RT (Fig. 2e–g; Sup-
plementary Fig. 2A–C).
Because DNA repair begins within seconds of damage29, we
were uncertain whether this decreased γ-H2AX staining meant
that nucleosides were preventing the induction of DNA damage
or facilitating its rapid repair. We therefore performed the
alkaline comet assay30, which measures physical DNA double-
strand and single-strand breaks31. When performed on ice to
arrest DNA repair, this assay measures only the induction of
DNA damage. When performed at warmer temperatures and
with longer incubation times after RT, this assay reflects both the
induction and repair of DNA damage. Nucleosides did not
change the amount of DNA damage induced when cells were
irradiated on ice and harvested immediately (Fig. 2h, i;
Supplementary Fig. 2D, E). However, exogenous nucleosides
decreased the DNA damage that was present after repair was
allowed to proceed at 37 °C for 0.5 and 4 h in two RT-sensitive
GBM cell lines, DBTRG-05MG (p < 0.01 for 0.5 h and p < 0.05 for
4 h) and GB-1 (p < 0.05 for 0.5 h and 4 h, Fig. 2h, i;
Supplementary Fig. 2D, E). Thus, supplementing nucleotide
pools in RT-sensitive GBMs facilitates the repair of RT-induced
DNA damage.
Inhibiting GTP synthesis radiosensitizes RT-resistant GBMs.
Based on the above data, we next asked if lowering nucleotide
pools would radiosensitize RT-resistant models of GBM. While
nucleotides can either be salvaged or synthesized de novo, most
GBMs are thought to rely on de novo nucleotide synthesis rather
than nucleotide salvage32. Consistent with this hypothesis, a 4-h
incubation with 15N-amide glutamine labeled nearly half of the
GMP, UMP, and CMP pools in the RT-resistant U87 GBM cell
line, indicating substantial activity of de novo nucleotide synth-
esis. Less AMP was labeled (~30%), possibly due to the larger
adenylate pool size (Supplementary Fig. 3A–D). These results
suggested that inhibiting de novo nucleotide synthesis might have
therapeutic utility in GBM.
Because guanylates were the metabolic pathway most asso-
ciated with RT-resistance (Fig. 1c, e), we elected to intervene on
this pathway (Fig. 3a). Mycophenolic acid (MPA) and its orally
bioavailable prodrug mycophenolate mofetil (MMF) inhibit GTP
synthesis by blocking the rate-limiting enzyme inosine monopho-
sphate dehydrogenase (IMPDH). This intervention inhibits de
novo GTP synthesis and also partially inhibits GTP salvage (if the
salvaged base is hypoxanthine, Fig. 3a). MPA and MMF are FDA-
approved to treat immune-mediated disorders, are being
investigated as anticancer therapeutics and have favorable
penetrance in the CNS where they are used for patients with
conditions such as neurosarcoidosis33–35. Treatment with a
clinically-relevant concentration of MPA (10 µM)36 reduced
GTP levels by more than tenfold, increased inosine
monophosphate levels by more than tenfold and increased ATP
levels 1.2-fold, consistent with inhibition of IMPDH and little
GTP generation from guanine (Fig. 3a–d).
MPA radiosensitized two RT-resistant cell lines (treatment
timeline shown as Supplementary Fig. 3E) in a concentration-
dependent fashion (Fig. 3e, f). ERs ranged from 1.2 ± 0.1 in both
U87 and A172 with 1 μM MPA treatment and 1.7 ± 0.3 in U87
MG and 2.3 ± 0.3 in A172 at 10 μM MPA, which is greater than
the radiosensitizing effects of temozolomide, the standard radio-
sensitizer used in GBM37. The radiosensitizing effects of MPA
were abrogated when cells were co-treated with exogenous
nucleosides (ER: 1.0 ± 0.03 in U87 MG and 1.2 ± 0.1 in A172,
Fig. 3e, f), indicating that MPA exerted its radiosensitizing effects
through nucleotide depletion rather than off-target effects. Unlike
in RT-sensitive GBM cell lines, exogenous nucleosides did not
further protect RT-resistant GBM cell lines from RT (Fig. 3e, f).
We speculate that RT-resistant cells are already rich in
nucleotides (Fig. 1c, d), which limits the ability of further
nucleoside supplementation to protect cells from RT.
The above findings were obtained in GBM cell lines that were
resistant to RT in our initial profiling. While tractable for
metabolomic and clonogenic survival assays, these immortalized
GBM models may not fully recapitulate the histopathologic or
molecular features of GBM tumors in patients38. We therefore
confirmed our findings in primary patient-derived GBM neuro-
sphere lines, referred to as HF2303 and MSP1239. These primary
GBM cells form neurospheres when grown in serum-free
conditions, are inherently resistant to RT and are thought to
represent the cellular subtypes that mediate GBM recurrence after
therapy40,41. Because neurospheres are not amenable to the
clonogenic survival assay, we instead performed a long-term
viability assay to assess the effects of RT. Primary neurospheres
were treated as shown in Supplementary Fig. 3E. Treatment with
MPA increased the RT-sensitivity of both HF2303 (ER: 1.4 ± 0.1)
and MSP12 (ER: 1.7 ± 0.4 for MSP12) neurospheres. MPA-
induced radiosensitization was reversed by exogenous nucleosides
(ER: 0.8 ± 0.3 for HF2303 and 0.8 ± 0.1 for MSP12, Fig. 3g, h).
Because inhibition of IMPDH with MPA can inhibit both de
novo and salvage GTP synthesis, it was unclear which pathway
was responsible for mediating RT-resistance. We therefore asked
if selectively inhibiting GTP salvage affected GBM RT-resistance.
Blocking IMPDH-dependent GTP salvage (Fig. 3a) by depleting
media hypoxanthine (from 30 µM in control media to absent in
experimental media), did not sensitize U87 MG cells to RT
(Supplementary Fig. 3F). We took an orthogonal approach in
neurospheres because their culture conditions contain
lower concentrations of hypoxanthine. Silencing HPRT1, the
gene encoding HGPRT, which salvages both hypoxanthine (to
form IMP) and guanine (to form GMP) (Fig. 3a), had no effect on
the radiosensitivity of MSP12 neurospheres (Supplementary
Fig. 3G, H). Hence, de novo GTP synthesis, rather than GTP
salvage, appears to play a dominant role in mediating GBM RT-
resistance.
Fig. 1 Increased levels of nucleobase-containing metabolites are associated with RT-resistance in GBM. a Clonogenic survival assays were performed on
the indicated GBM cell lines to determine Dmid (the linear area under the clonogenic survival curve). Data are presented as mean ± SEM from 3 to 7
biologic replicates. b RT-resistant (U87 MG and A172) and RT-sensitive (KS-1 and U118 MG) GBM cell lines were irradiated with 8 Gy, followed by γ-H2AX
flow cytometry analysis at 0, 0.5, 2, or 24 h following RT. Data are presented as mean ± SEM from 3 biologic replicates. c Metabolites were grouped into
pathways and an average pathway-level correlation with RT-sensitivity was determined. Only the pathways significantly correlated with RT-sensitivity are
shown. d Two RT-resistant (U87 MG and A172) and two RT-sensitive (KS-1 and U118 MG) GBM cell lines were irradiated with 8 Gy, and harvested 2 h
after RT and analyzed by targeted LC-MS/MS (4 biologic replicates per cell line). Fold-change values for each metabolite were determined based on
unirradiated matched cell line controls and then averaged for the two resistant (left) or sensitive (right) cell lines. e Pathways with downregulated
metabolites post-RT that are significantly correlated with RT-sensitivity are shown (Pearson’s correlation; p= 0.0001 for guanylates; p= 0.02 for
glutathione; p= 0.03 for nucleotide sugar, p= 0.0495 for adenylates.). Source data are provided as a Source Data file.
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Depleting GTP slows the repair of RT-induced DNA damage.
We reasoned that GTP depletion may sensitize GBMs to RT by
slowing DSB repair, much as nucleoside supplementation pro-
moted DSB repair. Consistent with this hypothesis, the
combination of MPA and RT increased γ-H2AX foci at various
time points compared with RT alone in both U87 MG and A172
cells (p < 0.01, Fig. 4a; p < 0.05, Fig. 4b, Supplementary Fig. 4A,
B). This increase (column 5 vs. 7, Fig. 4c, d) was rescued by the
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Fig. 2 Supplementing nucleoside pools promotes DNA repair and RT-resistance in GBM. a A schematic timeline of treatment in the RT-sensitive cell
lines. U118 MG, DBTRG-05MG, or GB-1 cells were treated with exogenous pooled nucleosides (Nuc; 8×) for 24 h, and retreated with nucleosides 2 h before
RT with indicated doses, followed by IF, comet assay, or clonogenic assay. b–d U118 MG, DBTRG-05MG, and GB-1 cells were treated as described in Fig. 2a,
followed by clonogenic assay. ER indicates the Enhancement Ratio, which is the ratio of Dmid control and Dmid treatment. ER > 1 indicates
radiosensitization while ER < 1 indicates radioprotection. Fig. b–d show representative figures from one of three biologic repeats for each cell line, each
performed in technical triplicate. Error bars indicate mean ± SEM from technical triplicates from that single representative experiment. In the lower left of
each graph, ER (mean ± SEM) from the three biologic replicates is shown. e–g Cells were treated as above and harvested for γ-H2AX foci IF staining at
indicated times post-RT. Data are presented as mean ± SEM from 3 biologically independent experiments. p values of 0.5, 2, 6, and 24 h are 0.0021,
0.0050, 0.0044, and 0.0035 for Fig. e; 0.0071, 0.0134, 0.0069, and 0.0056 for Fig. f; 0.0140, 0.0007, 0.0093, and 0.0035 for Fig. g–i. DBTRG-05MG or
GB-1 cells were treated as above and harvested at different time points for alkaline comet assay. Cells were irradiated and harvested on ice for the 0 h time
point (4 Gy; 0 h). Data are presented as mean ± SEM from 3 (h) or 4 (i) biologically independent experiments. p values of 0, 0.5 and 4 h are 0.4996,
0.0019, and 0.0145 for Fig. h; 0.8050, 0.0152, and 0.0080 for Fig. i. Fig. e–i: *p < 0.05 and **p < 0.01, ***p < 0.001 compared with control. The p values
indicated in Fig. e–i were obtained by two-tailed unpaired student's t test. Source data are provided as a Source Data file.
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Fig. 3 Inhibiting GTP synthesis radiosensitizes RT-resistant GBM cell lines and patient-derived neurospheres. a Purine synthesis schematic. R5P:
Ribose 5-phosphate; IMP: inosine monophosphate; GTP: Guanosine-5’-triphosphate; ATP: Adenosine triphosphate; IMPDH: Inosine-5’-monophosphate
dehydrogenase; HGPRT: hypoxanthine-guanine phosphoribosyltransferase; MPA: mycophenolic acid. b–d U87 MG cells were treated with MPA (10 μM)
for 24 h, and then harvested and analyzed by targeted LC-MS/MS. Data are presented as mean ± SEM from four biologic replicates. p values are <0.0001,
<0.0001, and 0.0237 for Fig. b–d, respectively. *p < 0.05, and ****p < 0.0001 compared with control. The p values indicated were obtained by two-tailed
unpaired student's t test. e, f After treatment with indicated conditions, cells were replated for colonogenic assay and colonies were stained and counted 10
to 14 days later. Data are presented as mean ± SEM from 4 separate experiments. g, h HF2303 or MSP12 neurospheres were treated as the timeline shown
in Supplementary Fig. 3e. In brief, cells were treated with nucleosides or MPA (10 µM), and retreated with nucleosides 2 h before RT. Cells were replated to
96-well plates (2000 cells/well) 24 h post-RT and cell viability were detected by the Celltiter-Glo kit ~7 days after replating. Fig. g and h are representative
figures from three biologically independent experiments. Error bars show mean ± SEM from representative experiments, which were performed in five
(g) or six (h) technical replicates. ER (mean ± SEM) of MPA from biologic replicates is shown on the lower left of each graph and is calculated as the GI50
of the control-treated cells divided by the GI50 of the MPA-treated cells. Source data are provided as a Source Data file.
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Fig. 4 Inhibiting GTP synthesis impairs DNA repair in a nucleoside-dependent fashion. a–b Cells were treated with 10 µM MPA for 24 h and then
irradiated with 4 Gy, and cells were harvested at indicated time point for γ-H2AX foci staining. Data are presented as mean ± SEM from three (a) or six
(b) biologic replicates. p values of 2, 6, and 24 h are 0.0074, 0.0088, and 0.0036 for Fig. a; 0.0220, 0.0273, and 0.0355 for Fig. b. RT-resistant cells or
neurospheres were treated with MPA (10 µM) and collected for IF γ-H2AX foci staining 6 h post-RT. Data are presented as mean ± SEM from three
biologically independent experiments in Fig. c–f. Fig. a–f, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. The p values indicated were obtained by two-
tailed unpaired student's t test. Source data are provided as a Source Data file.
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administration of exogenous nucleosides (p < 0.01 in U87 MG
and p < 0.001 in A172, column 7 vs. 8; Fig. 4c, d; Supplementary
Fig. 4C, D). Similarly, MPA increased γ-H2AX foci in primary
neurospheres (p < 0.01 for HF2303 and p < 0.01 for MSP12, col-
umn 5 vs. 7), which was reversed by nucleoside treatment (p <
0.001 forHF2303, p < 0.0001 for MSP12; column 7 vs. 8; Fig. 4e, f;
Supplementary Fig. 4E, F). Hence, inhibition of de novo purine
synthesis impairs DNA repair and radiosensitizes GBM in a
nucleoside-dependent fashion in both RT-resistant GBM cell
lines and primary patient-derived GBM neurospheres.
Purines, not pyrimidines, govern RT-resistance in GBM. To
understand more precisely which nucleotides were mediating RT-
resistance and DNA repair in GBM, we used teriflunomide42,43,
an FDA-approved inhibitor of dihydroorotate dehydrogenase
(DHODH), a rate limiting enzyme in de novo pyrimidine
synthesis (Supplementary Fig. 5A). Teriflunomide decreased
pyrimidines concentrations in GBM cells (Supplementary
Fig. 5B–F), but did not radiosensitize RT-resistant GBM cell lines
(Fig. 5a, b), or impair the ability of these cell lines to repair RT-
induced DSBs as measured by γ-H2AX foci (Fig. 5c, d; Supple-
mentary Fig. 5G, H).
We then asked whether the pyrimidine or purine components
were responsible for the ability of pooled nucleosides to protect
GBM from RT (Fig. 2). In the RT-sensitive DBTRG-05MG cell
line, purines alone (adenosine and guanosine) promoted the
repair of RT-induced DSBs nearly as much (~90%) as pooled
nucleosides (Fig. 5e and Supplementary Fig. 5I). Similar results
were seen in the RT-sensitive GB-1 cell line, where purines
promoted DSB repair by ~64% compared with pooled nucleo-
sides (Fig. 5f and Supplementary Fig. 5J). Pyrimidines alone
(cytidine, uridine, and thymidine), did not promote the repair of
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Fig. 5 Modulating pyrimidine pools has minimal effects on GBM DNA repair and RT-resistance. a, b U87 MG and A172 cells were treated with varying
doses of teriflunomide (Teri) for 24 h, and then irradiated. Cells were replated for colonogenic assay 24 h post-RT. Individual plots show data from one of
three biologic replicates and error bars indicate mean ± SEM of technical replicates from that experiment. ER show the mean ± SEM from all three biologic
replicates. c, d Cells were treated with 20 µM teriflunomide for 24 h and then irradiated with 4 Gy, and cells were harvested at indicated time point post-RT
for γ-H2AX foci staining. Data points are averages (mean ± SEM) from three biologic replicates. Cells were treated with pooled nucleosides (Nuc; 8×), or a
combination of Adenosine+Guanosine (A+G), or Cytidine+ Thymidine+Uridine (C+ T+U) for 24 h, and retreated with indicated nucleosides 2 h
before RT (4 Gy), followed by IF γ-H2AX foci staining 6 h post-RT. For Fig. e–g, data are presented as mean ± SEM from four (e, f) or three (g) biologically
independent experiments. Source data are provided as a Source Data file.
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f; Supplementary Fig. 5I, J). In HF2303 neurospheres, purine
nucleosides stimulated DNA repair as much as (~110%) pooled
nucleosides, while pyrimidines alone had a more modest effect
(Fig. 5g and Supplementary 5K). Thus, purines appear to play a
greater role in mediating DNA repair and RT-resistance in GBM
than do pyrimidines.
Inhibiting GTP synthesis radiosensitizes flank models of GBM.
We next sought to understand whether inhibiting GTP synthesis
could overcome GBM RT-resistance in tumor models in vivo. We
utilized MMF, which is an orally bioavailable pro-drug of MPA
that is FDA-approved to treat organ rejection. Because the U87
cell line was one of the most RT-resistant models in our initial
profiling (Fig. 1a), we initially used this model in vivo. Once flank
xenografts were 80–100 mm3 in size, they were randomized to
receive vehicle control, RT alone, MMF or MMF+ RT (Supple-
mentary Fig. 6A). We analyzed a subset of tumors 2 h after their
second RT dose. Numerous guanylates increased shortly follow-
ing RT, and this increase was abrogated when RT was combined
with MMF (Supplementary Fig. 6B). γ-H2AX levels also
increased post-RT, and increased further when RT was combined
with MMF (Supplementary Fig. 6C). MMF by itself induced little
γ-H2AX. The remaining mice continued with treatment to assess
tumor growth. Tumor growth was modestly slowed by treatment
with RT or MMF alone, but nearly arrested by the combination of
RT and MMF (Supplementary Fig. 6D). These changes were also
significant when analyzed as time to tumor tripling (p < 0.05,
MMF+ RT vs. RT; p < 0.05, MMR+ RT vs. MMF; p < 0.0001,
MMF+ RT vs. Control; Supplementary Fig. 6E).
To extend these findings into models more representative of
GBM biology in patients, we performed similar experiments using
flank tumors established from HF2303 and MSP12 neurospheres
(Fig. 6a). Consistent with the immortalized xenograft model,
multiple guanylates were elevated in HF2303 xenografts harvested
2 h after receiving their second RT dose. This increase was again
abrogated when MMF was administered along with RT (Fig. 6b).
MMF increased RT-induced γ-H2AX in both HF2303 and
MSP12 tumors (Fig. 6c). In animals continuing treatment to
assess tumor response, single agent MMF and RT modestly
slowed both HF2303 and MSP12 tumor growth. However,
combined MMF and RT significantly slowed tumor growth
(Fig. 6d, e), and increased the time to tumor tripling (Fig. 6f, g).
Median days to tumor tripling are 12 (Control), 16 (MMF), 23
(RT), and 33 (MMF+ RT) for HF2303 and 10 (Control), 12
(MMF), 13.5 (RT), and 19 (MMF+ RT) for MSP12, respectively.
The effects of treatments on normal tissues were minimal, as
reflected by relatively unchanged body weight during drug
treatment (Supplementary Fig. 6F, G). Consistent with the
observed treatment efficacy, combined MMF and RT decreased
the expression of the cell proliferation marker Ki-67 compared
with either treatment in isolation in all three models (Supple-
mentary Fig. 6H).
MMF augments RT efficacy in an orthotopic PDX model of
GBM. Because the GBM microenvironment and poor intracranial
exposure can limit drug efficacy, we sought to understand whe-
ther MMF would be efficacious in an intracranial GBM model.
We engineered luciferase expression into GBM38, which is an
intrinsically RT-resistant PDX model of primary GBM from the
Mayo Clinic Brain Tumor Patient-Derived Xenograft National
Resource44. After intracranial surgeries, tumor initiation was
confirmed by bioluminescence imaging and tumor-bearing ani-
mals were randomized to receive control, RT, MMF, or MMF+
RT+MMF (Fig. 7a). Tumor bioluminescence was profoundly
decreased by combined RT and MMF treatment, but only slightly
affected by MMF or RT when given alone (Fig. 7b, c). Consistent
with these observations, combined MMF and RT prolonged
mouse survival (median 62 days) compared with control treat-
ment (median 42 days), while MMF (median 43 days) or RT
(median 45.5 days) alone had minimal effects (Fig. 7d). Hence,
inhibition of GTP synthesis with MMF can overcome GBM RT-
resistance intracranially.
High IMPDH1 is associated with inferior GBM patient survi-
val. Finally, we asked if these data were reflected in the outcomes
of patients with GBM. We identified 208 patients from the
Cancer Genome Atlas Pan-Cancer Atlas with newly diagnosed
primary IDH wild type gliomas (so-called “molecular GBMs”)
whose samples had passed the Pan-Cancer quality assurance, the
vast majority of whom received RT45. Increased transcript
expression (>median) of IMPDH1, the rate limiting enzyme in de
novo GTP synthesis and target of MPA/MMF, was associated
with inferior overall survival (HR 0.60, 95% CI 0.43–0.82, p=
0.002). The IMPDH1 high and low groups were similar with
respect to known clinical and pathologic determinants of survival
including age (median 60 vs. 59 years) and MGMT promoter
methlation (39 vs. 40%). We could not quantify the extent of
resection in IMPDH1 high and low groups and therefore do not
know if this key variable is partially responsible for the apparent
decreased survival in patients with low IMPDH1 expression46.
Increased expression of the rate limiting enzymes in de novo ATP
synthesis (ADSS: adenylosuccinate synthase and ADSL: adenylo-
succinate lyase) or de novo pyrimidine synthesis (DHODH:
dihydroorotate dehydrogenase and CAD: carbamoyl-phosphate
synthetase 2, aspartate transcarbamylase, and dihydroorotase)
were not associated with decreased survival in patients with newly
diagnosed IDH wild type glioma (Fig. 7e).
We performed an exploratory analysis of the small number (n
= 22) of patients in the PANCAN dataset with IDH mutant
GBM. Neither IMPDH1 nor IMPDH2 were prognostic in these
patients (Supplementary Fig. 7A). Intriguingly, high expression of
DHODH, a rate-limiting step in de novo pyrimidine synthesis,
was adversely prognostic in patients with IDH mutant GBM,
which suggests that further investigation of pyrimidine biosynth-
esis could be interesting in gliomas with an IDH mutation.
Together, these in vitro, in vivo and patient-level data suggest that
purines, especially GTP, mediate RT-resistance, and DNA repair
in IDH wild type GBM and that inhibition of GTP synthesis
could be a promising therapeutic strategy for GBM, especially
when combined with RT.
Discussion
Intratumoral genomic heterogeneity in GBM has limited the
efficacy of personalized targeted therapies. To overcome this
barrier, we sought to discover metabolic pathways that caused
RT-resistance in GBM independently of genotype. By analyzing
how intracellular metabolites correlated with GBM RT-resistance,
we found that low levels of nucleobase-containing metabolites
were strongly associated with sensitivity to RT. This association
was causal, as supplementing GBM cells with exogenous
nucleosides protected them from RT by promoting the repair of
RT-induced DSBs. The protective effects of these nucleosides
were primarily due to purines rather than pyrimidines. This
relationship between nucleotide pools and RT-resistance has
important therapeutic applications. Depleting intracellular GTP
pools with FDA-approved drugs sensitized GBM cell lines to RT
by slowing the repair of dsDNA breaks. Inhibiting salvage GTP
synthesis or depleting pyrimidine pools had no such effects.
These results were recapitulated in neurosphere, flank-xenograft,
and intracranial PDX models of GBM. In addition, high
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Fig. 6 MMF augments RT efficacy against immortalized GBM xenografts. a A schematic timeline of HF2303 and MSP12 flank models. HF2303 and
MSP12 xenograft GBM models were established and randomized as described in “Methods”. Mycophenolate mofetil (MMF) (120mg/kg) was
administered via oral gavage once daily beginning the day prior to RT and ending the day after. MMF was given 2 h before RT and held on weekends (six
total doses). RT (2 Gy/fraction) was administered over four daily fractions on weekdays. b, c A subset of tumors harvested 2 h after receiving the second
RT dose were analyzed by LC-MS/MS (b), or were ground and lysed for immunoblotting assay with indicated antibodies. The bands were quantified using
Image J 2.0 software and the quantified numbers were labeled under each band (c). Fig. c are representative figures from three biologically independent
experiments. d, e Tumor volumes for the indicated treatment groups are normalized to the individual tumor sizes defined on day 1. Error bars indicate
mean ± SEM from ten tumors of 5 mice per group. f, g Kaplan–Meier estimates of time to tumor tripling. p values for Control vs. RT are 0.0117 Fig. f and
0.0089 Fig. g; Control vs. MMF are 0.0133 Fig. f and 0.0324 Fig. g; Control vs. MMF+ RT are <0.0001 Fig. f, g; RT vs. MMF+ RT are 0.0026 Fig. f and
0.0009 Fig. g; MMF vs. MMF+ RT are <0.0001 Fig. f and 0.0006 Fig. g; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. The p values were obtained by
the log-rank (Mantel–Cox) test. Source data are provided as a Source Data file.
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Fig. 7 Purine metabolism mediates RT resistance in an orthotopic patient-derived GBM model. a Luciferase-positive RT-resistant GBM38 patient-
derived xenograft cells were orthotopically implanted and, 28 days later, brain tumor-bearing mice were randomized to treatment with drug vehicle, RT,
MMF, or MMF+ RT (3–5 animals per group). MMF was administrated from Day 28 to 38 (11 doses), and RT was given from Day 29 to 32 and Day 35 to
38, respectively. b Mice were treated with 150mg/kg D-luciferin and imaged 10min post-injection. c Total flux of equal-area ROIs at each time point were
normalized to flux at the first day of treatment and used to approximate tumor progression. Data are presented as mean ± SEM from three (MMF+ RT) or
four (Control, RT, MMF) independent mice per group. d Kaplan–Meier survival curve. Mice were monitored daily and euthanized when they developed
neurologic symptoms. p value for RT vs. MMF+ RT is 0.0409; 0.0213 for MMF vs. MMF+ RT; 0.0151 for Control vs. MMF+ RT; *p < 0.05. The p value
was obtained by the log-rank (Mantel–Cox) test. e Kaplan–Meier overall survival curve of 208 patients from the Pan-Cancer Atlas with newly diagnosed
IDH wild type GBM. High and low groups are defined by median expression of key rate limiting enzymes of nucleotide synthesis. The p values were
obtained using the log-rank (Mantel–Cox) test. f Working model. RT induces DSBs in GBMs. High de novo purine synthesis promotes GBM survival by
stimulating dsDNA repair, cell survival and recurrence after RT. Supplementing cells with purines (A+G) promotes RT-resistance while inhibiting de novo
purine synthesis with mycophenolic acid (MPA) or mycophenolate mofetil (MMF) promotes RT-sensitivity. Source data are provided as a Source Data file.
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expression of the rate limiting enzyme in de novo GTP synthesis
was associated with inferior survival in IDH wild type GBMs but
not in IDH mutant GBMs. In summary, we have found that
purine, and especially guanylate, metabolism mediates RT-
resistance in GBM and can be targeted with FDA-approved
drugs (Fig. 7e).
These results add to a growing body of literature indicating that
purine synthesis contributes to the aggressive behavior of GBM
and other cancers47. High rates of de novo purine and pyrimidine
synthesis promote the maintenance and tumorigenic capacity of
glioma-initiating cells, which are thought to contribute to therapy
resistance and tumor recurrence in GBM48,49. Our data suggest
that the high rates of de novo, but not salvage, purine synthesis in
these tumorigenic cells may contribute to their enhanced ability
to repair RT-induced DNA damage and mediate tumor recur-
rence. De novo purine synthesis can generate both GTP and ATP.
De novo GTP synthesis is preferentially upregulated in GBM,
while de novo ATP synthesis is similarly active in both normal
brain tissue and GBM. This upregulation of GTP synthesis pro-
motes tRNA and rRNA synthesis, nucleolar transformation, and
GBM proliferation50. This importance of GTP was recapitulated
in our studies, as guanylates were most strongly correlated with
GBM RT-resistance and inhibiting de novo GTP synthesis alone
was sufficient to overcome GBM RT-resistance.
These findings suggest that MMF should be evaluated for
therapeutic benefit in patients with GBM, particularly in combi-
nation with RT. Because MMF is FDA-approved for other indi-
cations, the barrier to clinical translation is low. Furthermore,
standard dosing of MMF appears to achieve active intracranial
concentrations, based on published pharmacokinetic studies34,
our own results in orthotopic GBM tumors, and activity in
patients with neurosarcoidosis35. Because normal glia and neural
stem cells have lower demands for GTP synthesis and may pre-
ferentially rely on salvage pathways50, such a therapeutic strategy
may have minimal normal tissue toxicity.
Like the small number of therapies with proven benefit in
GBM, inhibitors of purine synthesis do not require a precise
oncogenic event for activity. Therefore, these inhibitors may have
clinical benefit despite the intratumoral genomic heterogeneity
that characterizes GBM. Indeed, many of the heterogeneous
oncogenic alterations that drive GBM including mutations,
deletions, or amplifications in PTEN, EGFR, and PIK3CA can
cause the similar metabolic phenotype of elevated de novo purine
synthesis18–20,51. Thus, a genomically heterogenous GBM7–9 may
exhibit a relatively homogeneous metabolic phenotype of elevated
de novo purine synthesis, which could be exploited ther-
apeutically to overcome RT-resistance.
Our study raises several questions. How purines, especially
GTP, regulate RT-resistance and dsDNA repair in GBM remains
to be defined. Because modulating pyrimidine levels did not cause
similar effects as modulating purines, we believe that this link is
likely due to active signaling, perhaps through a GTP-activated
protein, rather than the more simplistic explanation that mod-
ulating nucleotide pools alters the availability of the substrates for
DNA repair. Our experiments were entirely carried out in models
of GBM without mutations in IDH1/2, which represent the vast
majority of GBMs in patients. Whether the rarer secondary
GBMs containing the IDH1 or IDH2 mutation exhibit a similar
relationship between de novo purine synthesis and therapy
resistance remains to be defined.
In summary, we have defined purine, and especially guanylate,
metabolism as a mediator of RT-resistance in GBM. These
findings have motivated the development of a clinical trial to test
whether MMF achieves effective concentrations in GBM tissue in
patients and whether it is safe and effective in combination with
RT for patients with this disease.
Methods
In vivo xenograft models. All mouse experiments were approved by the Uni-
versity Committee on Use and Care of Animals at the University of Michigan. C.B-
17 SCID mice (female, 4–7 weeks old) were obtained from Envigo and maintained
in specific pathogen-free conditions. University of Michigan’s Unit for Laboratory
Animal Medicine (ULAM) ensured that the housing temperature was kept at 74 °F,
relative humidity between 30 and 70%, and was on a light/dark cycle of 12 h on/12
h off. Cells were resuspended in 1:1 PBS:Matrigel (BD Biosciences) and sub-
cutaneously injected into the bilateral dorsal flanks of mice. Once the tumor
volume reached ~80–100 mm3, mice we randomized into four arms, including
vehicle control (0.5 (w/v) methylcellulose/0.1% (v/v) Polysorbate 80), MMF alone,
RT alone, or combined RT and MMF. MMF (120 mg/kg) and/or RT (2 Gy/frac-
tion) were administered as shown in Fig. 6a and Supplementary Fig. 6A. A subset
of tumors analyzed for biologic endpoints (including mass spectrometry and
immunoblotting) was taken 2 h after their second RT (or sham RT) dose. The
remainder of the animals continued with treatment and had tumor volume and
body weight measured three times weekly. Tumor volumes were determined using
digital calipers and the formula (π/6) (Length ×Width2).
Orthotopic patient-derived xenograft model. RT-resistant GBM38 PDXs44 were
obtained from Dr. Jann Sarkaria and propagated as subcutaneous flank tumors in
female CB17-SCID mice. After short-term explant culture, cells were infected with
lentiviruses harboring fluc (lenti-LEGO-Ig2-fluc-IRES-GFP-VSVG) and enriched
for GFP-positive populations by FACS, followed by subcutaneous injection into the
flanks of mice to propagate GBM tissue. GBM cells expressing luciferase were then
isolated from the PDX tumors for orthotopic implantation in 6-week-old male and
female Rag1-KO mice (B6.129s7-RAG1 tm/Mom/J) obtained from the Jackson
Laboratory. After mouse anesthetization, a small scalp incision (<1 cm) was made,
and a burr hole was produced at coordinates of 1 mm forward and 2 mm lateral
from the bregma. Cells (~5 × 105) were then injected at a depth of 3 mm at a rate of
1 µL/min. Carprofen (5 mg/kg) was subcutaneously administered daily for 48 h
following procedure.
Treatment regimens for randomized brain tumor-bearing mice were initiated
4 weeks post implantation as shown in Fig. 7a. To assess the bioluminescence of
brain tumors, mice were treated with 150 mg/kg D-luciferin by intraperitoneal
injection and then imaged 10 min later under anesthesia (2% isoflurane inhalation)
using an IVIS™ Spectrum imaging system (PerkinElmer). Bioluminescence values
for mice euthanized midway through bioluminescence experiments were imputed
using most recent measurement prior to euthanization.
Mass spectrometry analysis. GBM cells or tumor samples were mixed or
homogenized in cold (−80 °C) 80% methanol. After centrifuging, samples were
normalized and lyophilized by speed vac. Dried pellets were resuspended in 1:1
methanol:H2O before LC-MS/MS analysis. Samples were run in triplicate on an
Agilent QQQ 6470 LC-MS/MS with ion pairing chromatography acquiring
dynamic multiple reaction monitoring for 226 metabolites with a delta retention
time (RT) window of 1 min. Data were preprocessed by applying a threshold area
of 3000 ion counts and a coefficient of variation of 0.5 among triplicates. All
chromatography analysis was done with Agilent MassHunter Quantitative Analysis
9.0.647.0. Raw data from these studies are included as a supplementary file (Sup-
plementary Data 2).
Initial cell metabolic profiling shown in Fig. 1c–e was performed by Metabolon,
Inc. Briefly, the 23 GBM cell lines were cultured in DMEM to 75–90% confluence
and harvested 1 h after addition of fresh media (Fig. 1c). Two RT-resistant cell lines
(U87 MG and A172) and two RT-sensitive cell lines (KS-1 and U118 MG, Fig. 1d,
e) were irradiated (8 Gy) and harvested after an additional 2 h incubation. The
global metabolic profiles of all the harvested cell samples (4–5 biologic replicates
per condition) were determined by Metabolon. Data from this profiling effort are
attached as a separate supplementary file (Supplementary Data 1).
15N-amide glutamine tracing study shown in Supplementary Fig. 3A–D was
performed at the University of Michigan Metabolomics Core. U87 MG cells labeled
with 2 mM 15N-amide glutamine were mixed in a solution of methanol,
chloroform, and water (8:1:1) for homogenizing and metabolite extraction. After
centrifuging, 100 µL of the extraction solvent was transferred to an autosampler vial
for LC-MS analysis. Nucleotide/Deoxynucleotide analysis was performed on an
Agilent system consisting of an Infinity Lab II UPLC coupled with a 6470 Triple
Quad (QqQ) mass spectrometer (Agilent Technologies, Santa Clara, CA.).
Metabolites were identified by matching the RT and mass (±10 ppm) to authentic
standards. Isotope peak areas were integrated using MassHunter Quantitative
Analysis vB.09.00 (Agilent Technologies, Santa Clara, CA)52.
Metabolic pathway analysis. The normalized metabolite intensity levels were
z-transformed (i.e., zero mean and unit variance across all cell lines) to enable
comparison on the same scale53. Metabolites with z-score below −1 or above +1
were assumed to be downregulated or upregulated. Metabolites were then grouped
into corresponding pathways based on annotation from Metabolon. A pathway-
level up or downregulation score was determined by calculating the ratio of the
total number of metabolites that were significantly up- or down-regulated to the
total metabolites measured in that pathway. This was then correlated with RT-
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resistance score using Pearson’s linear correlation function in MATLAB. The
pathways with significant correlation (p < 0.05) were also found to be significant
after Benjamin–Hochberg false discovery rate correction (FDR < 0.1). Significantly
correlated pathways were then visualized on a human metabolic network map
(Supplementary Fig. 1H) using the iPath pathway explorer54.
TCGA clinical and molecular data. TCGA Pan-Cancer Atlas LGG and GBM
cohorts were used for survival analysis and gene expression profiling55. For the
purposes of the current study, curation of these cases was performed to include
only IDH wild type primary/untreated samples, WHO grades II–IV. We further
excluded cases based on those that were masked (“Do_not_use”) according to the
Pan-Cancer Atlas sample quality annotations (http://api.gdc.cancer.gov/data/
1a7d7be8-675d-4e60-a105-19d4121bdebf). From the initial 1118 cases identified in
the LGG and GBM project, 208 IDH wild type primary tumors were used for
further analyses. Of the 208 IDH wild type TCGA cases we used for survival
analyses, there were 137 patients from the “Glioblastoma Multiforme” study (and
thus were grade IV by histologic criteria). A total of 71 patients were identified
from the LGG dataset who had either or both of TERT promoter mutation, the +7/
−10 signature, and EGFR amplification. If one of these are present, it now satisfies
the criteria for Glioblastoma, WHO grade IV56. To further differentiate between
IDH wild type and mutant GBM, we included 22 patients with IDH mutant
gliomas, which are either grade 4 by histology or by the presence of CDKN2A/B
homozygous deletion.
Gene expression data (RNA-seq) from the LGG and GBM cohorts was
downloaded from cBioPortal (http://www.cbioportal.org/, accessed 9/29/2019).
RSEM-normalized expression values were then stratified into low and high expressing
groups using a median cutoff. Overall survival was used as the clinical endpoint and
survival analytics were obtained from the TCGA Pan-Cancer Clinical Data Resource
(TCGA-CDR). Survival curves were generated using the Kaplan–Meier method and
significance assessed using the log rank test. Statistical significance was set at p < 0.05.
Anonymized clinical data was obtained from the above publicly available sources.
Thus, neither informed consent nor IRB approval was sought.
Statistical methods. Clonogenic survival, γ-H2AX foci formation, comet assay,
Ki-67 IHC staining, and metabolite level analysis after MPA and teriflunomide
treatment were analyzed by unpaired two-tailed t-tests using GraphPad Prism
Version 8 with the Holm-Sidak method employed to account for multiple com-
parisons when appropriate. Tumor volume of GBM xenografts was normalized to
100% at the first day for each group. Time to tumor tripling in each group was
determined by identifying the earliest day on which it was at least three times as
large as on the first day of treatment and then estimated by the Kaplan–Meier
method and compared using the log-rank test. Significance threshold was set at p <
0.05.
Cell lines and additional methods. Detailed source of GBM cell lines is outlined
in Supplementary Table 1. Additional methodological detail, including a descrip-
tion of cell culture and reagents, clonogenic survival assay, CCLE analysis, gene
knockdown, immunofluorescence, flow cytometry, long-term neurosphere assay,
alkaline comet assay, immunoblotting, and immunohistochemistry accompanies
this manuscript in the Supplementary Methods.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data underlying Figs. 1a–e, 2b–i, 3b–h, 4a–f, 5a–g, 6b–g, 7c–e and Supplementary
Figs. 1A, B, F, G, 3A–D, F–H, 5B–F, 6B–H, and 7A are provided as a Source Data file.
The metabolomic data of Fig. 1c–e (Supplementary Data 1), and Fig. 3b–d, Fig. 6b and
Supplementary Fig. 5B–F, 6B (Supplementary Data 2) for this article are available as
Supplementary Information files. Uncropped images for immunoblots are shown in
Supplementary Figs. 8. Flow cytometry gating information is shown in Supplementary
Figs. 9 and 10. Further data are available from the corresponding author upon reasonable
request. Source data are provided with this paper.
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